About Us 🔊 New Interview – Inside Cardiawave’s Journey with the EIC Scaling Club🎙️ Cardiawave’s presentation at LSI 2025 Jan 13, 2026 HeleneCardiawave 0
Press Release VALVOSOFT®, the first non-invasive treatment for severe Symptomatic Aortic Stenosis (sSAS) from Cardiawave receives CE Marking Dec 4, 2025 HeleneCardiawave 0
Press Release VALVOSOFT®, le premier traitement non invasif de la Sténose Aortique Sévère symptomatique (sSAS) développé par Cardiawave, obtient le marquage CE Dec 4, 2025 HeleneCardiawave 0
Events 📢 Cardiawave’s Valvosoft® to be presented at PCR London Valves 2025! Nov 6, 2025 HeleneCardiawave 0
Press Release Cardiawave renforce son leadership avec la nomination de Jonathan Freeman, Président du CA Oct 30, 2025 HeleneCardiawave 0
Scientific PublicationsFocused Ultrasound Foundation’s article regarding the safety of Cardiawave’s Focused Ultrasound Treatment of Aortic Valve Stenosis! Jul 24, 2023 READ MORE
Clinical StudiesPatient Inclusion Completed for Cardiawave’s “Valvosoft® Pivotal Study”! Jul 17, 2023 READ MORE
EventsBest oral presentation award for Clara Magnier, our CIFRE PhD student – July 5 – Paris Jul 5, 2023 © CNRS READ MORE
About Us 🔊 New Interview – Inside Cardiawave’s Journey with the EIC Scaling Club🎙️ Cardiawave’s presentation at LSI 2025 Jan 13, 2026 HeleneCardiawave 0
Press Release VALVOSOFT®, the first non-invasive treatment for severe Symptomatic Aortic Stenosis (sSAS) from Cardiawave receives CE Marking Dec 4, 2025 HeleneCardiawave 0
Press Release VALVOSOFT®, le premier traitement non invasif de la Sténose Aortique Sévère symptomatique (sSAS) développé par Cardiawave, obtient le marquage CE Dec 4, 2025 HeleneCardiawave 0
Events 📢 Cardiawave’s Valvosoft® to be presented at PCR London Valves 2025! Nov 6, 2025 HeleneCardiawave 0
Press Release Cardiawave renforce son leadership avec la nomination de Jonathan Freeman, Président du CA Oct 30, 2025 HeleneCardiawave 0
